February 12, 2014 - USA Adis R&D Insight SLA – Pipeline Town Hall Ben Weintraub and Jeff...
-
Upload
megan-holt -
Category
Documents
-
view
222 -
download
1
Transcript of February 12, 2014 - USA Adis R&D Insight SLA – Pipeline Town Hall Ben Weintraub and Jeff...
April 10, 2023 - USA
Adis R&D Insight
SLA – Pipeline Town Hall
Ben Weintraub and
Jeff Southwood
WHY ADIS R&D INSIGHT
April 10, 2023 - USA 2
Why? – Experience, Expertise, and Timeliness
Editorial Staff—150+ highly qualified (PhD, MD, PharmD) staff in-house—Average writing experience = 7-10 years (some up to 20 years)—Expertise across extensive range of therapeutic areas—Rigorous training program—Global focus
inThought Team—10 years experience covering pharma for Wall Street—Practicing physicians on staff to provide the clinician’s perspective—Network of medical experts
Daily updates from company contacts, press releases, international conferences, company websites, and journals
April 10, 2023 - USA 3
Comprehensive pipeline of preclinical, clinical, and launched compounds, updated daily using sources
from around the world.
Why? – Scientific/Clinical Emphasis
In-depth reviews of launched products and compounds in development worldwide covering all indications, countries, and phases
Concise summaries of pivotal clinical trials with links to full study profiles in Adis Clinical Trials Insight
Comprehensive drug development history provides timeline for key events and milestones throughout the development process
Detailed synopsis of pharmacokinetics, pharmacodynamics, and adverse events broken out by indication
Global phase of development table documents progress by country/region
April 10, 2023 - USA 4
Extensively referenced profiles provide a narrative of each drug’s developmental history.
Why? – inThought Commercial Assessments
inThought Approvability Index—Probability of FDA approval—Available for all drugs in active clinical development—Based on specific factors in each phase of clinical development and
benchmarked against historical parameters—Absolute probability of approval as well as comparison to similar
agents
Revenue Forecasts—Models assess both currently approved and developmental drugs—Top-down, based on the addressable patient population —Forecasts seven years in the future and three years in the past—Models incorporate Wolters Kluwer’s Healthcare Analytics prescription
data
April 10, 2023 - USA 5
Single-source estimates provide a consistent view of FDA approvability and worldwide revenue potential.
Why? – Ease of Use
Intuitive search by name, class, mechanism, organization, development role, indication, patient segment, phase, and country
Refine search results to include drugs that are only available for licensing, small molecules, fixed combinations, orphan drugs, fast track status, biological, in active development
Save searches, send searches, revise searches
Alerts based on saved searches
April 10, 2023 - USA 6
Gilead Products by Phase17
Launched10 Phase II
28 Discontinued - Preclinical
12 No Develop-
ment Reported
Why? – Workflow Solution Tools
Create Excel and PowerPoint tables and graphs from search results
Export to Excel or HTML
Exported charts have links to the database that do not require a password – email to anyone
April 10, 2023 - USA 7
Adis R&D Insight: Gilead Pipeline
Indication Phase Country
BSF 208075 Pulmonary hypertension Marketed European Union, Japan, United Kingdom, USA
GSK1325760A Pulmonary hypertension Phase III Canada, South America
Letairis Idiopathic pulmonary fibrosis
Discontinued(III) Australia, European Union, Israel, New Zealand, North America,
Volibris®
Forvade® Cytomegalovirus infections
Marketed Australia, Brazil, Canada, European Union, New Zealand, Switzerland, USA
GS 504 Polyomavirus infections Discontinued(III) USA
HPMPC Herpes simplex virus infections
Discontinued(II) Canada, USA
Vistide® Human papillomavirus infections
Discontinued(II) European Union, USA
Kaposi's sarcoma Discontinued(II) USA
Viral infections Discontinued(II) USA
Human papillomavirus infections
Discontinued(Clinical) Belgium
Molluscum contagiosum Discontinued(Clinical) USA
Cancer Discontinued(Preclinical) USA
Rheumatic disorders Discontinued(Preclinical) Czech Republic
Daunorubicin citrate liposome injection
Kaposi's sarcoma Marketed Australia, Denmark, Finland, Spain, Sweden,
DaunoXome® Acute myeloid leukaemia Discontinued(II) USA
VS 103 Brain cancer Discontinued(II) USA
Breast cancer Discontinued(II) USA
Colorectal cancer Discontinued(II) USA
Lymphoma Discontinued(II) United Kingdom
Multiple myeloma Discontinued(II) USA
Non-Hodgkin's lymphoma Discontinued(II) USA
Ovarian cancer Discontinued(II) USA
Prostate cancer Discontinued(II) USA
Acute lymphoblastic leukaemia
Discontinued(I) France
Chronic lymphocytic leukaemia
Discontinued(I) USA
6 Daunorubicin liposomal
5 Cidofovir
2 Ambrisentan
Drug SynonymsDrug Development Phase
Why? – Customer Support
Ask-The-Expert service provides complimentary access to our team of scientific experts, financial analysts, and physician consultants to help answer your specific questions
April 10, 2023 - USA 8
EMERGING TRENDS
April 10, 2023 - USA 9
Emerging Trends
Pharma is increasing the pace and sophistication of licensing and acquisitions, driving a need for better information to screen candidates and more diverse and detailed information about each product
Emerging markets: visibility into India, China, and other emerging markets are becoming critical
Pharma doesn’t want a data dump…they need a strategic partner who can synthesize, condense, and summarize all the available information in a meaningful way that provides insights that are commercially relevant to their specific business and business issues
Mix of secondary and primary information, mix of facts and opinions
April 10, 2023 - USA 10
Drug database users want a single source for clinical data summaries, forecasts, commercial information, and business
development solutions.
FUTURE DEVELOPMENTS
April 10, 2023 - USA 11
Future Development
Single site source for clinical, commercial, deals, and regulatory
Incorporate other content from within Wolters Kluwer—Sales and managed care content from Source Healthcare Analytics—Clinical Trial content from Adis Clinical Trials Insight—Epidemiology and clinical content from UpToDate— inThought Research alert content
Partner with 3rd parties for additional commercial content—Consensus revenue estimates—Consensus launch dates—Patent expiry
April 10, 2023 - USA 12
Building a single source for clinical data summaries, forecasts, commercial information, and business
development solutions.